APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Antiviral Drugs for the Treatment of Hepatitis C (HCV)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Growth and Trends Forecast to 2032

Report ID 173966780127 December 2025103 pages

Choose your research edition.

Industry ResearchAntiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Antiviral Drugs for the Treatment of Hepatitis C (HCV) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Antiviral Drugs for the Treatment of Hepatitis C (HCV) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antiviral Drugs for the Treatment of Hepatitis C (HCV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV) include AbbVie, Asegua Therapeutics, Bristol Myers Squibb, Gilead Sciences, Merck, Ascletis Pharma, Cosunter pharmaceutical, Kawin Technology and Sanhome Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Antiviral Drugs for the Treatment of Hepatitis C (HCV) market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antiviral Drugs for the Treatment of Hepatitis C (HCV).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Company

AbbVie

Asegua Therapeutics

Bristol Myers Squibb

Gilead Sciences

Merck

Ascletis Pharma

Cosunter pharmaceutical

Kawin Technology

Sanhome Pharmaceutical

Beijing Sihuan Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Segment by Type

NS3/4A Protease Inhibitors

NS5A Inhibitors

NS5B Polymerase Inhibitors

Other

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Segment by Application

Hospital and Clinic

Pharmacy

Other

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiviral Drugs for the Treatment of Hepatitis C (HCV) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiviral Drugs for the Treatment of Hepatitis C (HCV).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antiviral Drugs for the Treatment of Hepatitis C (HCV) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Antiviral Drugs for the Treatment of Hepatitis C (HCV) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of NS3/4A Protease Inhibitors Table 2. Major Company of NS5A Inhibitors Table 3. Major Company of NS5B Polymerase Inhibitors Table 4. Major Company of Other Table 5. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (K Units) Table 7. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Type (2021-2026) Table 8. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (US$ Million) Table 9. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Type (2021-2026) Table 10. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type (2021-2026) & (US$/Unit) Table 11. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2027-2032) & (K Units) Table 12. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Type (2027-2032) Table 13. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2027-2032) & (US$ Million) Table 14. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Type (2027-2032) Table 15. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type (2027-2032) & (US$/Unit) Table 16. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (K Units) Table 17. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (K Units) Table 19. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (K Units) Table 23. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (US$ Million) Table 26. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Trends Table 27. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Drivers Table 28. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Opportunities and Challenges Table 29. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Restraints Table 30. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Company (2021-2026) Table 32. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Company (2021-2026) & (K Units) Table 33. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Share by Company (2021-2026) Table 34. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Major Company Production Sites and Headquarters Table 37. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company, Product Type & Application Table 38. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2021-2026) & (K Units) Table 43. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Region (2021-2026) Table 44. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2021-2026) & (US$ Million) Table 45. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Region (2021-2026) Table 46. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2027-2032) & (K Units) Table 48. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Region (2027-2032) Table 49. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2027-2032) & (US$ Million) Table 50. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Region (2027-2032) Table 51. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (K Units) Table 54. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Application (2021-2026) Table 55. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (US$ Million) Table 56. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Application (2021-2026) Table 57. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application (2021-2026) & (US$/Unit) Table 58. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2027-2032) & (K Units) Table 59. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Application (2027-2032) Table 60. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2027-2032) & (US$ Million) Table 61. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Application (2027-2032) Table 62. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application (2027-2032) & (US$/Unit) Table 63. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (K Units) Table 64. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (K Units) Table 66. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (K Units) Table 70. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (US$ Million) Table 73. AbbVie Company Information Table 74. AbbVie Business Overview Table 75. AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 77. AbbVie Recent Development Table 78. Asegua Therapeutics Company Information Table 79. Asegua Therapeutics Business Overview Table 80. Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 82. Asegua Therapeutics Recent Development Table 83. Bristol Myers Squibb Company Information Table 84. Bristol Myers Squibb Business Overview Table 85. Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 87. Bristol Myers Squibb Recent Development Table 88. Gilead Sciences Company Information Table 89. Gilead Sciences Business Overview Table 90. Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 92. Gilead Sciences Recent Development Table 93. Merck Company Information Table 94. Merck Business Overview Table 95. Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 97. Merck Recent Development Table 98. Ascletis Pharma Company Information Table 99. Ascletis Pharma Business Overview Table 100. Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 102. Ascletis Pharma Recent Development Table 103. Cosunter pharmaceutical Company Information Table 104. Cosunter pharmaceutical Business Overview Table 105. Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 107. Cosunter pharmaceutical Recent Development Table 108. Kawin Technology Company Information Table 109. Kawin Technology Business Overview Table 110. Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 112. Kawin Technology Recent Development Table 113. Sanhome Pharmaceutical Company Information Table 114. Sanhome Pharmaceutical Business Overview Table 115. Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 117. Sanhome Pharmaceutical Recent Development Table 118. Beijing Sihuan Pharmaceutical Company Information Table 119. Beijing Sihuan Pharmaceutical Business Overview Table 120. Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 122. Beijing Sihuan Pharmaceutical Recent Development Table 123. YiChang HEC ChangJiang Pharmaceutical Company Information Table 124. YiChang HEC ChangJiang Pharmaceutical Business Overview Table 125. YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 127. YiChang HEC ChangJiang Pharmaceutical Recent Development Table 128. Chia Tai Tianqing Pharmaceutical Company Information Table 129. Chia Tai Tianqing Pharmaceutical Business Overview Table 130. Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 132. Chia Tai Tianqing Pharmaceutical Recent Development Table 133. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 134. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026) & (K Units) Table 135. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021-2026) Table 136. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Forecast by Country (2027-2032) & (K Units) Table 137. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share Forecast by Country (2027-2032) Table 138. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country (2021-2026) & (US$ Million) Table 140. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Country (2021-2026) Table 141. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share Forecast by Country (2027-2032) Table 143. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 144. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026) & (K Units) Table 145. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021-2026) Table 146. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Forecast by Country (2027-2032) & (K Units) Table 147. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share Forecast by Country (2027-2032) Table 148. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country (2021-2026) & (US$ Million) Table 150. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Country (2021-2026) Table 151. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share Forecast by Country (2027-2032) Table 153. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 154. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026) & (K Units) Table 155. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021-2026) Table 156. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Forecast by Country (2027-2032) & (K Units) Table 157. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country (2021-2026) & (US$ Million) Table 160. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Country (2021-2026) Table 161. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share Forecast by Country (2027-2032) Table 163. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 164. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026) & (K Units) Table 165. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021-2026) Table 166. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Forecast by Country (2027-2032) & (K Units) Table 167. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share Forecast by Country (2027-2032) Table 168. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country (2021-2026) & (US$ Million) Table 170. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Country (2021-2026) Table 171. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share Forecast by Country (2027-2032) Table 173. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 174. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026) & (K Units) Table 175. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021-2026) Table 176. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Forecast by Country (2027-2032) & (K Units) Table 177. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share Forecast by Country (2027-2032) Table 178. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country (2021-2026) & (US$ Million) Table 180. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Country (2021-2026) Table 181. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share Forecast by Country (2027-2032) Table 183. Key Raw Materials Table 184. Raw Materials Key Suppliers Table 185. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Distributors List Table 186. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Customers List Table 187. Research Programs/Design for This Report Table 188. Authors List of This Report Table 189. Secondary Sources Table 190. Primary Sources List of Figures Figure 1. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Image Figure 2. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size (2021-2032) & (US$ Million) Figure 4. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (2021-2032) & (K Units) Figure 5. NS3/4A Protease Inhibitors Image Figure 6. Global NS3/4A Protease Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 7. NS5A Inhibitors Image Figure 8. Global NS5A Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 9. NS5B Polymerase Inhibitors Image Figure 10. Global NS5B Polymerase Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Type 2025 VS 2032 Figure 15. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Type in 2025 Figure 16. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Type in 2025 Figure 17. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Type in 2025 Figure 18. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Type in 2025 Figure 21. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital and Clinic Image Figure 28. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 29. Pharmacy Image Figure 30. Global Pharmacy Sales YoY Growth (2021-2032) & (K Units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Application 2025 VS 2032 Figure 35. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Application in 2025 Figure 36. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Application in 2025 Figure 37. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Application in 2025 Figure 38. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Application in 2025 Figure 41. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share in Value by Application in 2025 Figure 45. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • NS3/4A Protease Inhibitors
  • NS5A Inhibitors
  • NS5B Polymerase Inhibitors
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • AbbVie
  • Asegua Therapeutics
  • Bristol Myers Squibb
  • Gilead Sciences
  • Merck
  • Ascletis Pharma
  • Cosunter pharmaceutical
  • Kawin Technology
  • Sanhome Pharmaceutical
  • Beijing Sihuan Pharmaceutical
  • YiChang HEC ChangJiang Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Type
  6. 1.3.1 NS3/4A Protease Inhibitors
  7. 1.3.2 NS5A Inhibitors
  8. 1.3.3 NS5B Polymerase Inhibitors
  9. 1.3.4 Other
  10. 1.4 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Type
  11. 1.4.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Trends
  2. 2.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Drivers
  3. 2.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Opportunities and Challenges
  4. 2.4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2026)
  2. 3.2 Global Top Players by Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (2021-2026)
  3. 3.3 Global Top Players by Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price (2021-2026)
  4. 3.4 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Major Company Production Sites & Headquarters
  6. 3.6 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company, Product Type & Application
  7. 3.7 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Tier 1, Tier 2, and Tier 3
4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Regional Status and Outlook
  1. 4.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Historic Market Size by Region
  3. 4.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Forecasted Market Size by Region
  7. 4.3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Application
  1. 5.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Application
  6. 5.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 AbbVie
  2. 6.1.1 AbbVie Company Information
  3. 6.1.2 AbbVie Business Overview
  4. 6.1.3 AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  6. 6.1.5 AbbVie Recent Developments
  7. 6.2 Asegua Therapeutics
  8. 6.2.1 Asegua Therapeutics Company Information
  9. 6.2.2 Asegua Therapeutics Business Overview
  10. 6.2.3 Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  12. 6.2.5 Asegua Therapeutics Recent Developments
  13. 6.3 Bristol Myers Squibb
  14. 6.3.1 Bristol Myers Squibb Company Information
  15. 6.3.2 Bristol Myers Squibb Business Overview
  16. 6.3.3 Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  18. 6.3.5 Bristol Myers Squibb Recent Developments
  19. 6.4 Gilead Sciences
  20. 6.4.1 Gilead Sciences Company Information
  21. 6.4.2 Gilead Sciences Business Overview
  22. 6.4.3 Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  24. 6.4.5 Gilead Sciences Recent Developments
  25. 6.5 Merck
  26. 6.5.1 Merck Company Information
  27. 6.5.2 Merck Business Overview
  28. 6.5.3 Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  30. 6.5.5 Merck Recent Developments
  31. 6.6 Ascletis Pharma
  32. 6.6.1 Ascletis Pharma Company Information
  33. 6.6.2 Ascletis Pharma Business Overview
  34. 6.6.3 Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  36. 6.6.5 Ascletis Pharma Recent Developments
  37. 6.7 Cosunter pharmaceutical
  38. 6.7.1 Cosunter pharmaceutical Company Information
  39. 6.7.2 Cosunter pharmaceutical Business Overview
  40. 6.7.3 Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  42. 6.7.5 Cosunter pharmaceutical Recent Developments
  43. 6.8 Kawin Technology
  44. 6.8.1 Kawin Technology Company Information
  45. 6.8.2 Kawin Technology Business Overview
  46. 6.8.3 Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  48. 6.8.5 Kawin Technology Recent Developments
  49. 6.9 Sanhome Pharmaceutical
  50. 6.9.1 Sanhome Pharmaceutical Company Information
  51. 6.9.2 Sanhome Pharmaceutical Business Overview
  52. 6.9.3 Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  54. 6.9.5 Sanhome Pharmaceutical Recent Developments
  55. 6.10 Beijing Sihuan Pharmaceutical
  56. 6.10.1 Beijing Sihuan Pharmaceutical Company Information
  57. 6.10.2 Beijing Sihuan Pharmaceutical Business Overview
  58. 6.10.3 Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  60. 6.10.5 Beijing Sihuan Pharmaceutical Recent Developments
  61. 6.11 YiChang HEC ChangJiang Pharmaceutical
  62. 6.11.1 YiChang HEC ChangJiang Pharmaceutical Company Information
  63. 6.11.2 YiChang HEC ChangJiang Pharmaceutical Business Overview
  64. 6.11.3 YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  66. 6.11.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments
  67. 6.12 Chia Tai Tianqing Pharmaceutical
  68. 6.12.1 Chia Tai Tianqing Pharmaceutical Company Information
  69. 6.12.2 Chia Tai Tianqing Pharmaceutical Business Overview
  70. 6.12.3 Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  72. 6.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country
  2. 7.1.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026)
  4. 7.1.3 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Forecast by Country (2027-2032)
  5. 7.2 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country
  6. 7.2.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country (2021-2026)
  8. 7.2.3 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country
  2. 8.1.1 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026)
  4. 8.1.3 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country
  6. 8.2.1 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country (2021-2026)
  8. 8.2.3 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country
  2. 9.1.1 Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country
  6. 9.2.1 Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country
  2. 10.1.1 South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026)
  4. 10.1.3 South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Forecast by Country (2027-2032)
  5. 10.2 South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country
  6. 10.2.1 South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country (2021-2026)
  8. 10.2.3 South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country
  2. 11.1.1 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country
  6. 11.2.1 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Value Chain Analysis
  2. 12.1.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Production Mode & Process
  7. 12.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Distributors
  10. 12.2.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst